The unrecognized compensation expense calculated under the fair-value method for stock options expected to vest as of December 31, 2018 and 2017 is approximately $6.5 million and $3.1 million, respectively, and is expected to be recognized over a weighted-average period of 3.1 years and 1.9 years, respectively.

Upon a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer or not, has the right, within six months from the date of acceptance of the tender offer, to petition the court to determine that the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions, the purchaser may provide in its offer that an offeree who accepted the tender offer will not be entitled to such rights.

Ma, X. et al. Hypoxia/Aglycemia-induced endothelial barrier dysfunction and tight junction protein downregulation can be ameliorated by citicoline. PLoS One. 8, e82604 (2013).

Sumu: High calorie diet, 5-7000/day. Low in sugar and processed foods. Intense exercise schedule leading to elevated adiponectin levels and insulin sensitivity. Low cholesterol, triglycerides, and glucose levels. Low visceral fat and ceramides ( toxic lipids)

As a side note: This article claims that aspirin can even help women getting pregnanthttp://www.mirror.co.uk/lifestyle/health/daily-aspirin-can-help-women-6672104 But this itself is not a study, but only a news article, so taken with care.

We do not currently carry “key person” insurance on the lives of members of senior management. The competition for qualified personnel in the pharmaceutical field is intense. Due to this intense competition, we may be unable to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel. Additionally, our ability to effectively recruit and retain qualified officers and directors could also be adversely affected if we experience difficulty in obtaining adequate directors’ and officers’ liability insurance. We may be unable to maintain sufficient insurance as a public company to cover liability claims made against our officers and directors. If we are unable to adequately insure our officers and directors, we may not be able to retain or recruit qualified officers and directors to manage the Company.

Adolor Corp (NASDAQGM:ADLR ) Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products.

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

Effects on cardiovascular risk are more complicated.  I have been unable to find direct comparisons of aspirin vs ibuprofen and others, but there is “circumstantial” evidence in the literature that aspirin slightly decreases CV risk, while all the others slightly increase risk.  Different studies rank the NSAIDs differently.  There is suspicion of the “coxib” drugs which many people find work well for arthritis, but the latest studies show this seems to be unfounded.  This study [2016] finds Celecoxib (Celebrex) is safer than either ibuprofen or naproxen (Alleve), and results in both lower CV risk and lower all-cause mortality.

Chan, K., Yin, M. & Chao, W. Effect of diallyl trisulfide-rich garlic oil on blood coagulation and plasma activity of anticoagulation factors in rats. Food Chem Toxicol. 45, 502–507 (2007).

The three classes of directors are Class I Directors, Class II Directors and Class III Directors. Allen Baharaff, Marshall Heinberg and Prof. Ran Oren serve as our Class II Directors until the close of the annual general meeting to be held in 2019; William Marth serves as our Class III Director until the close of the annual general meeting to be held in 2020; and Shmuel Nir and Dr. Carol Brosgart serve as our Class I Directors until the close of the annual general meeting to be held in 2021. In addition, our shareholders meeting held on June 7, 2017, resolved to re-elect Ms. Tali Yaron-Eldar and Dr. David Sidransky as the Company’s external directors for a term of three years, commencing as of June 12, 2017.

Hi Mark, The great problem is translation from basic science to clinical medicine. I think system works very well for new brand name drugs. Big pharma happy to spend few hundred million on clinical trials and have billions in profits. Gilead curing Hep C and near cure of AIDS is extraordinary success story. True that system doesn’t work for generic drugs, but they can be used off label. However, I greatly prefer FDA over anarchy. The big problem is one thing humans are really great at is being liars and cheats.